Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Facilitation of working memory in humans by a d2 dopamine receptor agonist.

Luciana M, Depue RA, Arbisi P, Leon A.

J Cogn Neurosci. 1992 Winter;4(1):58-68. doi: 10.1162/jocn.1992.4.1.58.

PMID:
23967857
2.

Dopaminergic modulation of working memory for spatial but not object cues in normal humans.

Luciana M, Collins PF.

J Cogn Neurosci. 1997 May;9(3):330-47. doi: 10.1162/jocn.1997.9.3.330.

PMID:
23965011
3.

Association analysis of 94 candidate genes and schizophrenia-related endophenotypes.

Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL.

PLoS One. 2012;7(1):e29630. doi: 10.1371/journal.pone.0029630. Epub 2012 Jan 13.

4.

Sensorimotor gating and clinical outcome following cognitive behaviour therapy for psychosis.

Kumari V, Premkumar P, Fannon D, Aasen I, Raghuvanshi S, Anilkumar AP, Antonova E, Peters ER, Kuipers E.

Schizophr Res. 2012 Feb;134(2-3):232-8. doi: 10.1016/j.schres.2011.11.020. Epub 2011 Dec 3.

5.

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M.

Schizophr Bull. 2013 Mar;39(2):417-35. doi: 10.1093/schbul/sbr153. Epub 2011 Nov 22. Review.

6.

Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.

Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT.

Arch Gen Psychiatry. 2012 Feb;69(2):121-7. doi: 10.1001/archgenpsychiatry.2011.129. Epub 2011 Oct 3.

PMID:
21969420
7.

Compensatory cognitive training for psychosis: who benefits? Who stays in treatment?

Twamley EW, Burton CZ, Vella L.

Schizophr Bull. 2011 Sep;37 Suppl 2:S55-62. doi: 10.1093/schbul/sbr059.

8.

D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.

Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC.

Schizophr Res. 2011 Sep;131(1-3):69-74. doi: 10.1016/j.schres.2011.05.029. Epub 2011 Jun 30.

9.

Are we studying and treating schizophrenia correctly?

Swerdlow NR.

Schizophr Res. 2011 Aug;130(1-3):1-10. doi: 10.1016/j.schres.2011.05.004. Epub 2011 Jun 8.

10.

A broad cortical reserve accelerates response to cognitive enhancement therapy in early course schizophrenia.

Keshavan MS, Eack SM, Wojtalik JA, Prasad KM, Francis AN, Bhojraj TS, Greenwald DP, Hogarty SS.

Schizophr Res. 2011 Aug;130(1-3):123-9. doi: 10.1016/j.schres.2011.05.001. Epub 2011 Jun 8.

11.

A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes.

Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P.

Am J Psychiatry. 2011 May;168(5):472-85. doi: 10.1176/appi.ajp.2010.10060855. Epub 2011 Mar 15.

PMID:
21406461
12.

Lack of relationship between acoustic startle and cognitive variables in schizophrenia and control subjects.

Hasenkamp W, Kelley M, Egan G, Green A, Wilcox L, Boshoven W, Lewison B, Duncan E.

Psychiatry Res. 2011 May 30;187(3):324-8. doi: 10.1016/j.psychres.2011.02.011. Epub 2011 Mar 11.

13.

Molecules, signaling, and schizophrenia.

Kvajo M, McKellar H, Gogos JA.

Curr Top Behav Neurosci. 2010;4:629-56. Review.

PMID:
21312416
14.

Functional brain imaging in schizophrenia: selected results and methods.

Brown GG, Thompson WK.

Curr Top Behav Neurosci. 2010;4:181-214. Review.

PMID:
21312401
15.

Memantine prevents hypoglycemia-induced decrements of the cerebral energy status in healthy subjects.

Willenborg B, Schmoller A, Caspary J, Melchert UH, Scholand-Engler HG, Jauch-Chara K, Hohagen F, Schweiger U, Oltmanns KM.

J Clin Endocrinol Metab. 2011 Feb;96(2):E384-8. doi: 10.1210/jc.2010-1348. Epub 2010 Nov 24.

PMID:
21106713
16.

Toxicology and safety of COMT inhibitors.

Haasio K.

Int Rev Neurobiol. 2010;95:163-89. doi: 10.1016/B978-0-12-381326-8.00007-7. Review.

PMID:
21095462
17.

Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment.

Ersche KD, Roiser JP, Lucas M, Domenici E, Robbins TW, Bullmore ET.

Psychopharmacology (Berl). 2011 Apr;214(4):779-89. doi: 10.1007/s00213-010-2087-1. Epub 2010 Nov 19.

18.

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.

Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A.

Schizophr Res. 2011 Feb;125(2-3):161-8. doi: 10.1016/j.schres.2010.09.015. Epub 2010 Dec 31.

PMID:
21075600
19.

Prefrontal cortical changes following cognitive training in patients with chronic schizophrenia: effects of practice, generalization, and specificity.

Haut KM, Lim KO, MacDonald A 3rd.

Neuropsychopharmacology. 2010 Aug;35(9):1850-9. doi: 10.1038/npp.2010.52. Epub 2010 Apr 28.

20.

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR.

Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21.

Supplemental Content

Support Center